



Novel Insights into Interstitial Lung Disease Diagnostics and Treatment

Guest Editors:

Dr. Jacobo Sellarés

Pneumology Department,
Respiratory Clinical Institute,
Hospital Clinic, IDIBAPS-
University of Barcelona,
University of Barcelona, 08007
Barcelona, Spain

Dr. Fernanda Hernandez

Pre-Doctoral Researcher,
Pneumology Department,
Respiratory Clinical Institute,
Hospital Clinic, IDIBAPS,
University of Barcelona, Villarroel
170, 08036 Barcelona, Spain

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Dear Colleagues,

In recent years, interstitial lung diseases (ILD) have presented an amazing development. The different international consensus have made it possible to clarify the different types of ILDs and optimal therapies, especially for idiopathic pulmonary fibrosis (IPF). Recent clinical trials have permitted the use of nintedanib and pirfenidone to reduce the progression of fibrotic disease. Additionally, the development of new techniques and the multidisciplinary discussion have been definitive in the progress of diagnosis accuracy. However, many areas are currently in development. The development of the “fibrotic pulmonary phenotype” definition in recent years and the beneficial effects of antifibrotics in this group has been one of the main recent advances in the field. This recent research has brought the ILD field into a novel and exciting moment. This Special Issue of *Journal of Respiration* aims to bring together current research and opinions on new concepts in diagnosis and treatment of interstitial lung diseases.

